Alaunos Therapeutics, Inc. (TCRT) stock
Close on Nov 16, 2026Market cap $4.06MP/E –Yield –
Alaunos Therapeutics, Inc. saw revenue fall 50.0% to $3.00K over the twelve months to Jun 30, 2026. Free cash flow was -$2.97M. At the latest close the market valued the company at $4.06M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $4.06M
- P/E ratio
- –
- Price to sales
- 1354.92
- Price to book
- 6.23
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.00K
- Net income
- -$4.01M
- EPS, diluted
- -$1.95
- Free cash flow
- -$2.97M
- Book value per share
- $0.27
- Diluted shares
- 2M
Trading
- Previous close
- $1.63
- Open
- $1.59
- Day's range
- $1.58 – $1.68
- Volume
- 61,521
- Average volume (20 days)
- 680,560
- 52-week range
- $0.72 – $4.50
- RSI (14 days)
- 44.2
- Volatility (1 year)
- 214.3%
- Relative volume
- 0.01×
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | TCRT | S&P 500 | Difference | TCRT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -39.2% | -3.1% | −36.1 pts | ||
| 3 months | -17.1% | -4.5% | −12.6 pts | ||
| Year to date | -50.5% | +9.4% | −59.8 pts | ||
| 1 year | -46.1% | +11.3% | −57.4 pts | ||
| 3 years | -84.8% | +70.4% | −155.2 pts | -46.6% | +19.4% |
| 5 years | -99.2% | +68.6% | −167.8 pts | -62.3% | +11.0% |
| 10 years | -99.8% | +297.7% | −397.5 pts | -47.6% | +14.8% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Alaunos Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- News
- News
- News
About Alaunos Therapeutics
Pharmaceutical Preparations
Alaunos Therapeutics, Inc. is a preclinical-stage biopharmaceutical enterprise concentrating on the discovery and development of orally administered small-molecule treatments for obesity and metabolic conditions, including metabolic dysfunction-associated steatotic liver disease. The company's lead therapeutic candidate, ALN1003, utilizes a differentiated, non-hormonal, and non-incretin mechanism of action intended to provide an alternative or complementary option to hormone-based incretin therapies. Alaunos previously operated as a clinical-stage oncology biotechnology firm focused on developing adoptive T-cell receptor engineered cell therapies before pivoting away from that portfolio.
Company profile, executives and historyAlaunos Therapeutics stock: common questions
What is Alaunos Therapeutics's stock price?
TCRT closed at $1.60 on Nov 16, 2026, down 1.84% on the day. Over the past 52 weeks it traded between $0.72 and $4.50.
What is Alaunos Therapeutics's market cap?
Alaunos Therapeutics was worth $4.06M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
What is TCRT's P/E ratio?
Alaunos Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.95), so it has no meaningful P/E ratio.
How much revenue does Alaunos Therapeutics make?
Alaunos Therapeutics reported revenue of $3.00K for the twelve months to Jun 30, 2026, down 50.0% from a year earlier.
Does Alaunos Therapeutics pay a dividend?
No. Alaunos Therapeutics has not paid a cash dividend over the last twelve months.
How has TCRT stock performed over the past year?
Including dividends, TCRT returned -46.1% over the past year, against +11.3% for the S&P 500.
How many TCRT shares are sold short?
0M shares were sold short at the latest FINRA report, 24.00% of the float, or 1.0 days of average trading volume.
Who are Alaunos Therapeutics's competitors?
Companies most similar to Alaunos Therapeutics by business, industry and size include SYBX, TLPH, CRVO, AZTR, GNLX.
See a number that looks wrong?